Thursday, July 3, 2025

PharmaTher Sponsors Research For Novel Delivery Of Ketamine

PharmaTher Inc (CSE: PHRM) this morning announced that it has entered into a sponsored research agreement. The agreement, which was signed with The Queen’s University of Belfast, will see the development of a patented hydrogel-forming microneedle patch for use with ketamine.

More specifically, the microneedle patch is being developed to work with KETABET, PharmaTher’s proprietary formulation for ketamine. The patch is being viewed as a potential next-generation treatment for neuropsychiatric, neurodegenerative and pain disorders, while limiting the potential for abuse and misuse. Microneedle delivery has the potential to overcome drawbacks associated with introvenous or nasal delivery methods.

The research is being led by Professor Ryan Donnelly, whom most recently published a paper on ketamine related to using a microneedle array as a delivery method. The MN tech, as the firm refers to it, is expected to overcome limitations related to drug quantities on the patch, while also improving the quantity of the drug that can permeate into the skin from the patch.

“We believe that ketamine and our proprietary ketamine formulation, KETABET™, delivered in the patented microneedle patch could potentially change the ways that mental health, neurodegenerative and pain disorders are treated.  We are pursuing the clinical development of KETABET™ MN patch to overcome the current limitations of ketamine and to unlock the known potential therapeutic value of ketamine as a prescription for regulatory approval worldwide.”

Fabio Chianelli, CEO of PharmaTher

The company is currently focused on developing a patch for FDA approval, which ultimately overcomes drawbacks related to other methods of delivery.

PharmaTher last traded at $0.22 on the CSE.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Gold Drilling Scaled to 60,000 Meters: How Big Can This Get? | Roger Rosmus – Goliath Resources

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Related News

PharmaTher Partners With TSRL For Microneedle Patch Development

PharmaTher Holdings (CSE: PHRM) has partnered with that of TSRL under a co-development agreement. The...

Tuesday, June 1, 2021, 08:21:51 AM

PharmaTher Applies For Pre-IND Meeting With US FDA For Ketabet

PharmaTher Holdings (CSE: PHRM) this morning announced that it continues to push forward with the...

Tuesday, June 15, 2021, 08:14:25 AM

PharmaTher To Commence Phase 2 Clinical Study On Ketamine In Q2 2021

Pharmather Inc (CSE: PHRM) is successfully progressing on the development of its proposed phase 2...

Thursday, February 4, 2021, 08:28:04 AM

PharmaTher Collaborates For Research On Psychedelic Microdosing Tech

PharmaTher Inc (CSE: PHRM) this morning announced that it will be conducting further research related...

Tuesday, February 23, 2021, 07:25:33 AM

PharmaTher: Maxim Initiates Coverage With US$1.50 Price Target

PharmaTher Holdings (CSE: PHRM) had its first initiation report that came out on June 28th....

Wednesday, June 30, 2021, 02:38:00 PM